Valuation : SANA AB

Market Cap 1.51B 157M 135M 127M 116M 217M 14.92B 218M 583M 7.62B 591M 578M 24.38B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.51B 157M 135M 127M 116M 217M 14.92B 218M 583M 7.62B 591M 578M 24.38B EV / Sales 2026 *
14.6x
EV / Sales 2027 * 7.2x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day-1.36%
1 week-4.63%
Current month-4.63%
1 month-19.19%
3 months-18.22%
6 months-25.17%
Current year-48.54%
1 week 10.43
Extreme 10.43
12.07
1 month 10.43
Extreme 10.43
14.39
Current year 10.43
Extreme 10.43
28.3
1 year 10.43
Extreme 10.43
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Buy

Founder

9,000 0.0065%
28/8/26 Buy

Chief Financial Officer

5,000 0.0036%
27/8/26 Buy

Director

4,188 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%-4.63%-17.72%+60.44% 159M
+2.02%+1.01%+45.58%+104.91% 67.82B
-0.41%-1.12%+35.32%+80.68% 63.22B
-1.11%+2.52%-13.93%+369.69% 27.58B
-4.92%-2.90%-12.27%-17.60% 26.06B
+1.69%+0.94%+33.46%+17.80% 25.38B
+1.12%+2.03%+23.61%-17.59% 19.89B
+6.04%+0.72%+239.13%+407.95% 17.4B
-0.49%-1.85%-6.87%+546.36% 14.95B
-2.27%+5.55%+52.24%+161.90% 14.62B
Average +0.03%+1.92%+37.85%+171.45% 27.71B
Weighted average by Cap. +0.30%+1.54%+38.83%+143.28%

Financials

2026 *2027 *
Net sales 103M 10.78M 9.26M 8.71M 7.95M 14.83M 1.02B 14.91M 39.92M 521M 40.44M 39.57M 1.67B 209M 21.86M 18.78M 17.67M 16.13M 30.1M 2.07B 30.26M 80.99M 1.06B 82.06M 80.29M 3.39B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
08/09/26 SEK 10.91 -1.36% 1,000,785
07/09/26 SEK 11.06 -6.35% 576,203
04/09/26 SEK 11.81 -0.34% 213,293
03/09/26 SEK 11.85 +0.51% 386,459
02/09/26 SEK 11.79 -0.42% 275,288

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!